In spite of recent progress in treatment strategies, 70% of advanced stage ovarian cancer cases relapse. Patients with recurrent disease are commonly characterized as platinum sensitive or platinum resistant. The definition of platinum-resistant disease includes patients who progress while receiving initial chemotherapy or within 6 months of completing initial platinum-based chemotherapy. If platinum free interval is less than 3-month, patients are defined as refractory disease and they have very little chance to respond to a platinum-based therapy. Platinum-sensitive patients are defined by recurrence after 6 or more months of the completion of initial chemotherapy. For a better subdivision of platinum sensitive group, patients with a more than 12-month interval are defined as highly sensitive disease and patients with 6 to 12 months are considered intermediate sensitive disease. Response to platinum retreatment increases with a longer interval from prior platinum treatment.
Last date updated on September, 2020